Leukemia

Although recent data show how promising a single-infusion of a specific CAR-T cell therapy may be for patients with acute lymphoblastic leukemia, an expert from the Moffitt Cancer Center notes that more research is needed for those deemed too ill to receive the treatment.

Patients with relapsed/refractory acute lymphoblastic leukemia may have prolonged survival with Blincyto, especially among those who undergo hematopoietic stem cell transplantation.

From the first COVID-19 vaccine doses becoming available for patients and their caregivers at a cancer center in Texas to community police officers delivering food to families impacted by cancer in Philadelphia, here’s what’s happening in the cancer landscape this week.

Over the past decade, advances in both diagnostics and therapeutics in a variety of blood cancers have turned certain diseases into chronic conditions.

Patients with chronic myeloid leukemia are living longer, some even stopping treatment, thanks to a plethora of targeted therapies.

Oncologists and researchers are racing to identify new therapies to help better treat a rare form of acute lymphoblastic leukemia.

Blood shortages during the COVID-19 pandemic have forced cancer centers to get creative to ensure patients with hematologic malignancies are able to get transfusions in a timely manner.

The Food and Drug Administration has granted the investigational therapy asciminib a breakthrough therapy designation for the treatment of certain adults with Philadelphia chromosome-positive chronic myeloid leukemia. The designation may allow for expedited review of the drug.

From one leukemia survivor organizing essential blood drives for patients with cancer as COVID-19 delays hit, to a kindergarten teacher handling a recurrence of ovarian cancer by continuing to teach her students through Zoom, here’s what’s happening in the cancer landscape this week.

The Food and Drug Administration approved the supplemental new drug application for Iclusig (ponatinib) to treat patients with chronic-phase chronic myeloid leukemia (CML) with resistance or intolerance to at least two prior kinase inhibitors.

Emily Whitehead was the first child to receive chimeric antigen receptor (CAR)-T cell therapy. Eight years later, she and her parents discuss her ongoing remission from acute lymphoblastic leukemia.